← back to search

Dieter Lemke

National Center for Tumor Diseases ·
Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer Mechanisms and Therapy, Cancer, Hypoxia, and Metabolism, and Ferroptosis and cancer prognosis.
h-index
18
citations
2,833
works
78
NIH funding
primary concept
email

Recent publications

AAMP is a binding partner of costimulatory human B7-H3
Neuro-Oncology Advances 2022cited by 16position: lastdoi
Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells
International Journal of Radiation Oncology*Biology*Physics 2021cited by 18position: middledoi
LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
Frontiers in Oncology 2020cited by 32position: lastdoi
Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche
JCI Insight 2019cited by 77position: middledoi
cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma
Journal of Neuro-Oncology 2019cited by 16position: middledoi
P11.07 LAPTM5 functions as a tumor suppressor via CD40 - NFêB pathway inhibition and represents a potential biomarker for temozolomide sensitivity in CD40 proficient glioblastoma
Neuro-Oncology 2019cited by 0position: lastdoi
Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Clinical Cancer Research 2018cited by 77position: middledoi
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
Molecular Cancer Research 2018cited by 35position: lastdoi
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas
Neuro-Oncology 2017cited by 303position: middledoi
P08.19 Resistance towards the MDM2 inhibitor idasanutlin is mediated via the NFkB pathway and IGFBP1 upregulation in glioblastoma
Neuro-Oncology 2017cited by 1position: middledoi
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy
Oncotarget 2016cited by 40position: firstdoi
Brain tumour cells interconnect to a functional and resistant network
Nature 2015cited by 1,112position: middledoi
Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity?
Journal of Neurochemistry 2014cited by 56position: firstdoi
Herg K+ Channel-Dependent Apoptosis and Cell Cycle Arrest in Human Glioblastoma Cells
PLoS ONE 2014cited by 54position: middledoi
Microenvironmental Clues for Glioma Immunotherapy
Current Neurology and Neuroscience Reports 2014cited by 53position: middledoi
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1
Nature Medicine 2013cited by 477position: middledoi
Glioma Invasion Confers Radioresistance
International Journal of Radiation Oncology*Biology*Physics 2012cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Wolfgang Wick · Heidelberger Institut für Radioonkologie14 papers (2012–2022)Michael Platten · German Cancer Research Center9 papers (2014–2020)Amir Abdollahi · German Cancer Research Center8 papers (2012–2022)Tobias Keßler · German Cancer Research Center5 papers (2017–2020)Anne Berberich · Klinikum Ludwigshafen5 papers (2018–2022)Maximilian Knoll · German Cancer Research Center4 papers (2019–2022)Felix Sahm · Heidelberg (Poland)4 papers (2016–2022)Jürgen Debus · NYU Langone Health4 papers (2012–2021)Zhen Dong · National Center for Tumor Diseases4 papers (2012–2020)Frank Winkler · TU Dresden4 papers (2016–2020)Nanina Hucke · Deutschen Konsortium für Translationale Krebsforschung4 papers (2018–2020)Benedikt Wiestler · TUM Klinikum4 papers (2014–2020)Sara Ciprut · National Center for Tumor Diseases3 papers (2017–2022)Jonas Blaes · Ludwigshafen University of Business and Society3 papers (2014–2018)Andreas von Deimling · Stiftung Schleswig-Holsteinische Landesmuseen3 papers (2018–2022)S Pusch · German Cancer Research Center3 papers (2019–2022)Philipp Seidel · Carl Zeiss (Germany)3 papers (2012–2021)Stefan Pusch · German Cancer Research Center3 papers (2018–2022)Thomas Hielscher · German Cancer Research Center3 papers (2017–2019)Zili Tang · Chongqing Normal University3 papers (2019–2021)